Finance

Beta
Lists
ACRV:NASDAQ
Acrivon Therapeutics Inc
$1.78
0.00%
(0.00) 1D
$1.78
0.00% (0.00)
Pre-market
Closed: Jun 30, 4:00:01 PM GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for ACRV...
Open
$1.76
High
$1.79
Low
$1.74
Mkt. cap
76.19M
Avg. vol.
406.80K
Volume
1.10K
52-wk high
$3.56
52-wk low
$1.15
EPS
-$2.00
Beta
1.89
Shares outstanding
42.80M
No. of employees
75
Open
$1.76
High
$1.79
Low
$1.74
Mkt. cap
76.19M
Avg. vol.
406.80K
Volume
1.10K
52-wk high
$3.56
52-wk low
$1.15
EPS
-$2.00
Beta
1.89
Shares outstanding
42.80M
No. of employees
75
News stories
From sources across the web
About Acrivon Therapeutics Inc
CEO-
Employees75
Founded2018
HeadquartersWatertown, Massachusetts, United States
SectorBiotechnology
Websiteacrivon.com
Analyst ratings
Based on 5 analysts giving stock ratings to ACRV in the past 3 months
Strong buy
Buy
5
Hold
0
Sell
0
12-month forecast
Based on 5 Wall Street analysts offering 12 month price targets for ACRV in the last 3 months.
Highest
Current $1.78
$19.00 (+967.42%)
Average
$10.50 (+489.89%)
Lowest
$7.00 (+293.26%)
Analyst
Recommendation
Action
Price target
Projected
Date
Jeff Jonas
Gabelli
Buy
Initiated
$8.00
+349.4%
06/15/2026
Jeff Jones
Oppenheimer
Buy
Initiated
$8.00
+349.4%
06/15/2026
Michael Okunewitch
Maxim Group
Buy
Reiterated
$7.00
+293.3%
05/18/2026
Marc Frahm
TD Cowen
Buy
Maintained
-
-
05/14/2026
Unknown Analyst
Oppenheimer
Buy
Reiterated
$8.00
+349.4%
05/14/2026
Emily Bodnar
H.C. Wainwright
Buy
Reiterated
$19.00
+967.4%
05/14/2026
Unknown Analyst
Jefferies
Buy
Maintained
$14.00
+686.5%
03/20/2026
Edward Tenthoff
Piper Sandler
Buy
Reiterated
$8.00
+349.4%
03/02/2026
Previous reportsAll values in USD
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in USD
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Revenue
-
-
-
-
Cost of goods sold
-
-
-
-
Cost of revenue
-
-
-
-
Research and development expenses
16.18M
13.65M
14.75M
15.17M
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
6.47M
6.04M
5.37M
4.74M
Operating expense
22.65M
19.69M
20.12M
19.90M
Total operating expenses
22.65M
19.69M
20.12M
19.90M
Operating income
-22.65M
-19.69M
-20.12M
-19.90M
Other non operating income
-87.00K
-53.00K
-753.00K
-129.00K
EBT including unusual items
-21.01M
-18.23M
-18.98M
-19.04M
EBT excluding unusual items
-21.01M
-18.23M
-19.42M
-19.04M
Income tax expense
-
-
-
-
Effective tax rate
-
-
-
-
Other operating expenses
-
-
-
-
Net income
-21.01M
-18.23M
-18.98M
-19.04M
Net profit margin
-
-
-
-
Earnings per share
-0.55
-0.47
-0.49
-0.49
Interest and investment income
1.73M
1.51M
1.25M
989.00K
Interest expense
-
-
-
-
Net interest expenses
1.73M
1.51M
1.25M
989.00K
Depreciation and amortization charges
-
-
-
-
EBITDA
-22.31M
-19.34M
-19.76M
-19.52M
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer

Research

What's on your mind?
What's going on with the markets today?
Explore what’s possible
Create a task
Deep Search
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer